Alzheimer’s disease (AD) targets the brain and can affect memory, thinking, judgement, and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. There are more than six million Americans living with Alzheimer’s, and that number is projected to rise to nearly 13 million by 2050.
Grayline Research Center is currently enrolling patients in Alzheimer’s disease studies aim at slowing the progression of mild-to-moderate AD, and also designed to boost a repair and regenerative pathway for brain cells, promoting brain health function.
To be considered for one of our Alzheimer’s research studies, patients must:
- Be ages 50 to 87 years old
- Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
- Have a family member or loved one who can be available as a study partner during the entire study
For more information and to see if you or your loved one pre-qualifies call us anytime! 940-322-1131